Companies Cryptocurrencies
Hepion Pharmaceuticals Inc
Hepion Pharmaceuticals Inc
Exchange: NasdaqCM
IPO Date: 07/02/2014
CEO: Dr. Robert Foster
Biotechnology Healthcare 🔗
  • HEPA
  • 1.55
  • 118149208
    market cap
  • -0.03000009
If you bought

shares of Hepion Pharmaceuticals Inc (HEPA) on
You would have made
Old Price $12 Current Price $12

Hepion Pharmaceuticals, Inc. engages in the development and commercialization of pleiotropic drug therapy for the treatment of chronic liver disease. The company is headquartered in Edison, New Jersey and currently employs 14 full-time employees. The firm is focused on the development of targeted therapies for liver disease arising from non-alcoholic steatohepatitis (NASH) and chronic hepatitis virus infection. Its lead oral drug candidate, CRV431, reduces liver fibrosis and hepatocellular carcinoma tumor burden in experimental models of NASH. CRV431 is also being developed for viral hepatitis-induced liver disease. CRV431 targets multiple biochemical pathways involved in the progression of liver disease.

Address: 399 Thornall St Edison NEW JERSEY 08837

Stay updated.